查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1717871

藥物動力學服務市場：按類型、按服務類型、按最終用戶 - 2025-2030 年全球預測

Pharmacokinetics Services Market by Type, Service Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

藥物動力學服務市場預計在 2024 年價值 11.9 億美元，在 2025 年成長至 13 億美元，到 2030 年達到 20.1 億美元，複合年成長率為 9.03%。

主要市場統計數據
基準年2024年 11.9億美元
預計2025年 13億美元
預測年份 2030 20.1億美元
複合年成長率（%） 9.03%

在新技術、複雜的藥物開發挑戰以及全球對高效治療解決方案日益成長的需求的推動下，藥物動力學服務市場即將經歷重大變革。隨著準確測量藥物的吸收、分佈、代謝和排泄變得至關重要，產業相關人員正在重新制定策略，以利用新的機會並解決新的障礙。分析方法的最新進展和新型治療劑的出現也要求在臨床研究和法規遵循方面採取靈活方法。

藥物動力學服務目前在藥物發現和開發中發揮關鍵作用，它能夠實現準確的數據收集和及時的干涉策略，以最佳化給藥方案並提高患者安全性。這個充滿活力的領域正在經歷將尖端的體外和體內測試與先進的計算模型相結合的綜合服務產品的激增。策略創新對於組織應對此複雜局面至關重要，可確保在廣泛的治療領域中取得可靠的成果和競爭差異化。

先進儀器和數位分析技術的引入使得藥物動力學具有更重要的戰略意義，成為製藥和生物技術產業的重要組成部分。因此，相關人員正在大力投資研發舉措，不僅是為了提高藥物評估的速度和準確性，也是為了遵守不斷發展的全球監管標準。目前的市場動態表明，對最尖端科技的投資和尋求合作研究機會對於該行業的持續成長和成功至關重要。

藥物動力學格局的變革

在快速的技術進步和不斷變化的客戶需求的推動下，藥物動力學服務領域正在經歷一場變革。近年來，自動化系統和數位資料平台的廣泛整合重新定義了傳統業務，使得藥物評估的方法更加全面。對創新技術的投資最大限度地減少了人為錯誤，提高了可重複性，並實現了滿足現代法律規範嚴格要求的即時數據分析。

此外，生物製藥創新和先進分析的融合導致了向個人化醫療的轉變。這種轉變不僅僅是技術上的實現；它反映了我們為完善對不同患者群體的藥物動力學的理解而做出的更廣泛的戰略努力。隨著產業的適應，融合體外和體內方法的解決方案將變得越來越重要，並且迫切需要整合各種研究模型來最佳化臨床結果。

這段快速變革時期時期也專注於加速藥物開發生命週期，同時確保最大的安全性和有效性。新的研究方案加上增強的模擬平台使研究人員能夠以前所未有的精確度預測藥物行為。這些發展促進了研究機構、技術合作夥伴和監管機構之間的跨職能合作，最終創造出一個數據主導創新可以改變藥物發現和治療開發格局的環境。

利用市場區隔洞察瞄準市場成長

徹底的細分分析將闡明藥物動力學服務市場的異質性，並突顯可能成長的領域。市場分析主要根據類型、服務類型和最終用戶屬性進行細分。根據類型，市場傳統上分為大分子藥物動力學服務和小分子藥物動力學服務。生技藥品和治療性蛋白質等大分子由於其複雜的結構，通常需要在藥物動力學評估中進行高度專業化的處理，而小分子則帶來了經典的分析挑戰，這些挑戰將繼續受益於迭代方法的改進。

此外，按服務類型細分凸顯了該行業對體外和體內測試的雙重關注。體外部分是基於實驗室的實驗，為早期藥物評估提供受控條件，提供省時且經濟的見解。另一方面，體內研究評估藥物在活體對像中的行為，提供對理解治療藥物的綜合藥物動力學特徵至關重要的真實世界觀點。提供這兩種類型的服務的能力使市場開發商能夠提供解決整個藥物開發生命週期的完整解決方案。

依最終用戶進一步細分，凸顯了需求方的多樣性和複雜性。該市場代表著廣泛的客戶群體，包括學術和政府研究機構、生物技術公司、委外研發機構和大型製藥公司。每個行業都有自己獨特的挑戰和要求，需要採用量身定做的方法進行研究和服務交付。技術創新者、學術機構和商業公司正在擴大調整他們的研究策略，將研究重點放在滿足監管和市場期望上。這種多方面的細分框架將使服務供應商能夠最佳化資源配置，調整調查方法，並最終實現客戶需求和市場產品之間的更好結合。從這種細分中獲得的策略見解將有助於使產品開發和市場進入策略與新興市場趨勢和客戶需求保持一致。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 慢性病發病率上升推動了藥物動力學服務的使用增加
      • 生技藥品和生物相似藥的成長將促進藥物動力學研究的應用
      • 由於醫藥品研究開發費用大幅增加，藥物動力學評估的重要性日益增加
    • 限制因素
      • 與影響藥物動力學服務的藥物概況相關的複雜性
    • 機會
      • 整合人工智慧提高藥物動力學研究的準確性和效率
      • 個人化醫療的日益普及正在推動藥物動力學服務市場的擴張
    • 任務
      • 法規環境複雜，變化頻繁，有地區差異
  • 市場區隔分析
    • 類型：個人化醫療需求不斷成長推動聚合物藥物動力學服務
    • 最終用戶：製藥和生技公司不斷增加的投資推動了藥物動力學服務的發展
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章藥物動力學服務市場（按類型）

  • 大分子藥物動力學服務
  • 小分子藥物動力學服務

第7章藥物動力學服務市場（依服務類型）

  • 體外
  • 體內

第8章藥物動力學服務市場（按最終用戶）

  • 學術和政府研究組織
  • 生技公司
  • 合約研究組織
  • 製藥公司

9.美洲藥物動力學服務市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

10. 亞太地區藥物動力學服務市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 11 章歐洲、中東和非洲藥物動力學服務市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Absorption Systems LLC
  • Allucent
  • Aurigene Pharmaceutical Services Ltd.
  • Certara
  • Charles River Laboratories, Inc.
  • Creative Bioarray
  • Eurofins Scientific SE
  • Evotec SE
  • Frontage Laboratories, Inc.
  • ICON PLC
  • Laboratory Corporation of America Holdings
  • LGC Limited by Cinven
  • NUVISAN Pharma Holding GmbH
  • Pacific BioLabs
  • Parexel International（MA）Corporation
  • Pfizer Inc.
  • PPD Inc. by Thermo Fisher Scientific Inc.
  • Premier Consulting
  • Reaction Biology Corporation
  • SGS SA
  • Svar Life Science AB
  • WuXi AppTec Co., Ltd.
  • XenoTech by BioIVT
  • Xyzagen
Product Code: MRR-C002B1C99681

The Pharmacokinetics Services Market was valued at USD 1.19 billion in 2024 and is projected to grow to USD 1.30 billion in 2025, with a CAGR of 9.03%, reaching USD 2.01 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.19 billion
Estimated Year [2025] USD 1.30 billion
Forecast Year [2030] USD 2.01 billion
CAGR (%) 9.03%

The pharmacokinetics services market is on the cusp of significant evolution, driven by emerging technologies, complex drug development challenges, and an ever-growing global demand for efficient therapeutic solutions. In a landscape where the accurate measurement of drug absorption, distribution, metabolism, and excretion is paramount, industry stakeholders are refining their strategies to harness new opportunities and address emerging impediments. Recent advancements in analytical methods and the advent of novel therapeutic agents have also necessitated an agile approach in clinical research and regulatory compliance.

Pharmacokinetics services now play a critical role in drug discovery and development by enabling precise data collection and timely intervention strategies that optimize dosing regimens and enhance patient safety. This dynamic field has witnessed a surge in integrated service offerings that combine state-of-the-art in-vitro and in-vivo studies with advanced computational modeling. As organizations navigate this complex terrain, strategic innovation remains a vital ingredient ensuring both robust results and competitive differentiation across a broad spectrum of therapeutic areas.

The introduction of sophisticated instrumentation and digital analytics has further elevated the strategic importance of pharmacokinetics, making it an indispensable facet within the pharmaceutical and biotech industries. Stakeholders are, therefore, investing considerably in research and development initiatives to not only improve the speed and accuracy of drug assessment but also to maintain compliance with evolving global regulatory standards. The current market dynamics signal that investing in cutting-edge technologies and seeking collaborative opportunities will be central to the sustained growth and success of the sector.

Transformative Shifts Reshaping the Pharmacokinetics Landscape

The pharmacokinetics services arena is experiencing transformative shifts powered by rapid technological advancements and evolving customer demands. Over recent years, the widespread integration of automated systems and digital data platforms has redefined traditional practices and enabled a more holistic approach to drug evaluation. Investment in innovative technology has minimized manual errors, enhanced reproducibility, and allowed for real-time data analysis that meets the stringent demands of modern regulatory frameworks.

Furthermore, the convergence of biopharmaceutical innovation and advanced analytics has led to a transformative pivot towards personalized medicine. This shift is not merely about technological adoption but also reflects a broader strategic effort to fine-tune the understanding of drug dynamics in diverse patient populations. As the industry adapts, solutions that merge in-vitro and in-vivo methodologies are assuming greater significance, driving a much-needed integration of various study models to optimize clinical outcomes.

This period of radical transformation is also marked by a keen focus on accelerating the drug development life cycle while ensuring maximum safety and efficacy. New investigative protocols, coupled with enhanced simulation platforms, are allowing researchers to predict drug behavior with unprecedented accuracy. Such developments have encouraged cross-functional collaborations among research institutions, technology partners, and regulatory agencies, ultimately fostering an environment in which innovation driven by data is transforming the landscape of drug discovery and therapeutic development.

Key Segmentation Insights for Targeted Market Growth

A careful segmentation analysis provides a clear view of the heterogeneous nature of the pharmacokinetics services market, illuminating the areas that are primed for growth. The market analysis is primarily categorized based on type, service type, and end-user demographics. When examining the segmentation based on type, the market has been traditionally divided between offerings for large molecules pharmacokinetics services and small molecules pharmacokinetics services. In many cases, large molecules, such as biologics and therapeutic proteins, demand highly specialized handling during pharmacokinetic assessment due to their complex structure, while small molecules bring forward classic analytical challenges that continue to benefit from iterative methodological enhancements.

In addition, segmentation in terms of service type highlights the dual focus of the industry around in-vitro and in-vivo studies. The in-vitro segment represents laboratory-based experiments that provide controlled conditions for early-stage drug evaluation, offering time-efficient and cost-effective insights. Conversely, in-vivo studies bring an essential real-world perspective to the table by evaluating drug behavior in live subjects, which is indispensable for understanding the comprehensive pharmacokinetic profile of therapeutic agents. The ability to provide both types of services allows market players to offer a complete suite of solutions that cater to the complete lifecycle of drug development.

Further segmentation by end-user underscores the diversity and complexity of the demand side. The market landscape encompasses a wide array of clients ranging from academic and government research institutes to biotechnology companies, contract research organizations, and large-scale pharmaceutical companies. Each segment brings its unique challenges and requirements, necessitating a tailored approach to research and service delivery. Technology innovators, academic institutions, and commercial players are increasingly aligning their research strategies to focus on delivers that meet both regulatory and market expectations. This multifaceted segmentation framework enables service providers to optimize resource allocation, tailor their research methodologies, and ultimately achieve better alignment between client needs and market offerings. The strategic insights drawn from this segmentation are instrumental in aligning product development and marketing strategies with emerging trends and client demands.

Based on Type, market is studied across Large Molecules Pharmacokinetics Services and Small Molecules Pharmacokinetics Services.

Based on Service Type, market is studied across In-Vitro and In-Vivo.

Based on End-User, market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies.

Emerging Regional Trends Shaping Market Dynamics

The pharmacokinetics services market is hugely influenced by regional trends that dictate regulatory frameworks, innovation capacities, and overall market dynamics. In the Americas, robust infrastructure and a highly developed network of research institutions foster a conducive environment for advanced pharmacokinetic investigations. This region benefits from well-established partnerships between academic and commercial entities, ensuring that the industry remains at the forefront of scientific breakthroughs and regulatory compliance.

Meanwhile, the combined region of Europe, Middle East, and Africa exhibits a diversified landscape where traditional research ecosystems meet emerging technological hubs. The interplay of different regulatory bodies within Europe and the growing innovation pockets in the Middle East and Africa have led to a flexible yet highly competitive environment. The region's diverse market conditions, varying from stringent regulatory oversight in Europe to more agile exploratory approaches in other parts, require service providers to adopt adaptable strategies that balance caution with innovation.

In Asia-Pacific, rapid economic growth combined with strong governmental support for pharmaceutical research has cemented the region's position as a key player in the global pharmacokinetics market. The emphasis on research and development, significant investments in biotechnology, and a surge in academic outputs have stimulated the demand for specialized pharmacokinetic services. The region benefits from a burgeoning talent pool and increased focus on integrating novel methodologies with traditional practices, setting the stage for accelerated market growth over the coming years. Overall, these regional insights point towards the need for global companies to adapt their strategies to cater to varying regional requirements while leveraging emerging trends for sustainable market expansion.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Driving Market Innovation

An analysis of the key companies active in the pharmacokinetics space reveals a competitive landscape where leaders are continuously pushing the boundaries of scientific innovation and service quality. Industry frontrunners include prominent firms such as Absorption Systems LLC and Allucent, which have built their reputations on delivering robust analytic methodologies that streamline early drug development phases. Other innovators like Aurigene Pharmaceutical Services Ltd. and Certara have become synonymous with excellence in both in-vitro and in-vivo studies, offering comprehensive solutions that address the intricate challenges of modern pharmacokinetics.

Major players such as Charles River Laboratories, Inc. and Creative Bioarray harness advanced technological platforms to deliver precise pharmacokinetic measurements and robust data analytics. The contributions of Eurofins Scientific SE and Evotec SE have redefined industry benchmarks with their combination of expertise and innovative research paradigms. Frontage Laboratories, Inc., ICON PLC, and Laboratory Corporation of America Holdings are further notable examples, consistently pushing the envelope in integrating research methods, streamlining processes, and ensuring regulatory adherence.

The market also sees significant contributions from industry leaders including LGC Limited by Cinven, NUVISAN Pharma Holding GmbH, Pacific BioLabs, Parexel International (MA) Corporation, and Pfizer Inc., whose strategic initiatives are aligned with advancing the drug development life cycle. Additional noteworthy players such as PPD Inc. by Thermo Fisher Scientific Inc., Premier Consulting, Reaction Biology Corporation, SGS SA, Svar Life Science AB, WuXi AppTec Co., Ltd., XenoTech by BioIVT, and Xyzagen collectively drive the competitive intensity and innovation within the pharmacokinetics services market. Their combined efforts in fostering collaboration, investing in new technologies, and streamlining study protocols set the stage for future advancements in drug development and tailored therapeutic strategies.

The report delves into recent significant developments in the Pharmacokinetics Services Market, highlighting leading vendors and their innovative profiles. These include Absorption Systems LLC, Allucent, Aurigene Pharmaceutical Services Ltd., Certara, Charles River Laboratories, Inc., Creative Bioarray, Eurofins Scientific SE, Evotec SE, Frontage Laboratories, Inc., ICON PLC, Laboratory Corporation of America Holdings, LGC Limited by Cinven, NUVISAN Pharma Holding GmbH, Pacific BioLabs, Parexel International (MA) Corporation, Pfizer Inc., PPD Inc. by Thermo Fisher Scientific Inc., Premier Consulting, Reaction Biology Corporation, SGS SA, Svar Life Science AB, WuXi AppTec Co., Ltd., XenoTech by BioIVT, and Xyzagen. Actionable Recommendations for Industry Leaders

Industry leaders must adopt strategic initiatives to maintain a competitive edge in the rapidly evolving pharmacokinetics landscape. First and foremost, investing in novel technological platforms is imperative for increasing both the speed and accuracy of drug evaluation. Leaders should explore opportunities to integrate artificial intelligence and machine learning into data analysis processes, which could streamline study designs and improve predictive outcomes in both in-vitro and in-vivo environments.

Additionally, fostering collaborative partnerships with academic institutions, regulatory agencies, and technology innovators will help bridge the gap between traditional pharmacokinetic methods and emerging trends. Such collaborations should aim at mutual knowledge exchange and co-development of tailored solutions that align with the evolving demands of drug safety and efficacy assessments. Industry players are encouraged to build robust, customizable platforms that can cater to unique client requirements, whether those are driven by the demands of large molecules or small molecules studies.

Adaptability is another crucial factor. Markets are increasingly segmented along various lines, including type, service delivery, and end-user profiles. Leaders must thus ensure that their service portfolios are sufficiently diverse to cater to academic, pharmaceutical, biotechnology, and contract research clients. By aligning service offerings with specific needs and embracing a modular approach to research capabilities, companies can better navigate regulatory changes and shifting market dynamics.

Moreover, advancing training programs and continuous education initiatives will be key to building a workforce prepared to tackle complex research challenges. Emphasizing skill development in emerging analytical techniques and cross-disciplinary methodologies can significantly enhance the quality of study outcomes. In conclusion, a forward-thinking approach that combines investment, collaboration, and meticulous resource management is essential for sustaining long-term growth and operational excellence in the pharmacokinetics services market.

Conclusion: Charting the Future of Pharmacokinetics Services

The evolving dynamics of the pharmacokinetics services market present both significant challenges and exciting opportunities. As the industry continues to integrate innovative technologies and adapt to diverse regional and client segmentation dynamics, the focus on delivering high-quality, compliant, and cost-effective study solutions remains paramount. The combined emphasis on technological advancement, strategic partnerships, and market-specific adaptations is laying a firm foundation for sustained growth and operational excellence.

This comprehensive market analysis underscores the importance of adopting a multifaceted approach that embraces changes in study design, regulatory landscapes, and digital transformation. By driving innovation, aligning service portfolios with specific client needs, and reinforcing global collaborations, industry stakeholders can set new benchmarks in pharmacokinetics services that support the rapid pace of drug discovery and therapeutic innovation. The future is bright for organizations that are prepared to invest in advanced methodologies and adapt dynamically to the constantly shifting market realities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of chronic diseases prompting expanded pharmacokinetic service utilization
      • 5.1.1.2. Growth in biologics and biosimilars fueling enhanced application of pharmacokinetic studies
      • 5.1.1.3. Significant growth in pharmaceutical R&D expenditure elevating the importance of pharmacokinetics assessments
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities associated with drug profiles impacting pharmacokinetics services
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of artificial intelligence for enhancing accuracy and efficiency of pharmacokinetics studies
      • 5.1.3.2. Increasing popularity of personalized medicine expanding market of pharmacokinetics service
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory landscapes with frequent amendments and regional differences
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Rising demand for personalized medicine boosts the pharmacokinetics services for large molecules
    • 5.2.2. End-User: Increasing investments from pharmaceutical & biotechnology companies driving pharmacokinetics services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmacokinetics Services Market, by Type

  • 6.1. Introduction
  • 6.2. Large Molecules Pharmacokinetics Services
  • 6.3. Small Molecules Pharmacokinetics Services

7. Pharmacokinetics Services Market, by Service Type

  • 7.1. Introduction
  • 7.2. In-Vitro
  • 7.3. In-Vivo

8. Pharmacokinetics Services Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic & Government Research Institutes
  • 8.3. Biotechnology Companies
  • 8.4. Contract Research Organizations
  • 8.5. Pharmaceutical Companies

9. Americas Pharmacokinetics Services Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Pharmacokinetics Services Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Pharmacokinetics Services Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. TC BioPharm and CareDx collaborate for enhanced monitoring in cell therapy clinical trial
    • 12.3.2. Sai Life Sciences enhances DMPK capabilities for large-scale collaborations
    • 12.3.3. Frontage Laboratories strengthens European market presence with Accelera acquisition
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Absorption Systems LLC
  • 2. Allucent
  • 3. Aurigene Pharmaceutical Services Ltd.
  • 4. Certara
  • 5. Charles River Laboratories, Inc.
  • 6. Creative Bioarray
  • 7. Eurofins Scientific SE
  • 8. Evotec SE
  • 9. Frontage Laboratories, Inc.
  • 10. ICON PLC
  • 11. Laboratory Corporation of America Holdings
  • 12. LGC Limited by Cinven
  • 13. NUVISAN Pharma Holding GmbH
  • 14. Pacific BioLabs
  • 15. Parexel International (MA) Corporation
  • 16. Pfizer Inc.
  • 17. PPD Inc. by Thermo Fisher Scientific Inc.
  • 18. Premier Consulting
  • 19. Reaction Biology Corporation
  • 20. SGS SA
  • 21. Svar Life Science AB
  • 22. WuXi AppTec Co., Ltd.
  • 23. XenoTech by BioIVT
  • 24. Xyzagen

LIST OF FIGURES

  • FIGURE 1. PHARMACOKINETICS SERVICES MARKET MULTI-CURRENCY
  • FIGURE 2. PHARMACOKINETICS SERVICES MARKET MULTI-LANGUAGE
  • FIGURE 3. PHARMACOKINETICS SERVICES MARKET RESEARCH PROCESS
  • FIGURE 4. PHARMACOKINETICS SERVICES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 15. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 17. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 23. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHARMACOKINETICS SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOKINETICS SERVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 146. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024